Eli Lilly's Olumiant approved for severe alopecia areata in children aged 12 and older
The U.S. Food and Drug Administration (FDA) has expanded the indication of Eli Lilly’s drug Olumiant (baricitinib) to treat severe alopecia areata in patients aged 12 years and above. This approval is based on data from a 36-week adolescent cohort within the phase 3 BRAVE-AA-PEDS study, which demonstrated efficacy for this age group. Alopecia areata is an autoimmune condition that causes hair loss, often severely impacting quality of life in adolescents and adults. The expanded indication allows Olumiant to be used as a treatment option for younger patients who previously had limited therapeutic choices. This development could increase the drug’s market reach and usage among pediatric populations. The approval reflects regulatory confidence in baricitinib's safety profile across age groups, following its prior authorization for adult use.
Tickers: $LLY